Boosting biologics and Contract Manufacturing at mAbxience facilitiesComunicacion Admon2023-04-03T09:26:50+02:00April 3, 2023|Read More
HK inno.N licenses in mAbxience’s denosumab biosimilartheoms2023-01-25T10:46:18+01:00January 25, 2023|Read More
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals markettheoms2022-08-01T17:18:20+02:00August 1, 2022|Read More
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxiencetheoms2022-04-19T22:57:54+02:00April 19, 2022|Read More
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxiencetheoms2022-05-25T23:46:17+02:00March 31, 2022|Read More
Cipla enters partnership to provide affordable oncology biosimilars to South Africatheoms2022-03-30T15:32:26+02:00March 30, 2022|Read More
Insud Pharma donation and assistance – Ukraine war situationtheoms2022-03-07T11:42:35+01:00March 7, 2022|Read More
mAbxience launches its CDMO platform to third partiestheoms2022-02-28T13:45:56+01:00February 28, 2022|Read More
